| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | AG2; GOB-4; HAG-2; XAG-2; PDIA17; HEL-S-116 |
| Entrez GeneID | 10551 |
| clone | 7H2H7 |
| WB Predicted band size | 20kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human AGR2 (AA: 21-175) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于AGR2抗体的3篇代表性文献(内容基于学术知识整理，具体信息建议通过PubMed等平台核实)：
---
1. **文献名称**：*"AGR2 antibodies: A novel diagnostic biomarker for pancreatic ductal adenocarcinoma"*
**作者**：Park et al.
**摘要**：该研究开发了针对AGR2蛋白的单克隆抗体，验证了其在胰腺导管腺癌(PDAC)组织中的高特异性表达，并通过免疫组化分析证明AGR2抗体可作为PDAC的潜在诊断标志物，与患者预后不良相关。
2. **文献名称**：*"The role of AGR2 in cancer cell invasion and antibody-based therapeutic targeting"*
**作者**：Thompson et al.
**摘要**：探讨了AGR2在乳腺癌细胞侵袭转移中的作用，发现其通过调控EMT(上皮-间质转化)促进转移。研究还测试了抗AGR2抗体的体外治疗潜力，证实其可抑制癌细胞迁移并增强化疗敏感性。
3. **文献名称**：*"AGR2 as a secretory biomarker of ER stress in colorectal cancer"*
**作者**：Zhang et al.
**摘要**：分析了AGR2在结直肠癌中的分泌特性，证明其表达与内质网应激相关。研究利用特异性抗体检测血清AGR2水平，提出其可能作为无创性液体活检指标用于早期筛查。
---
**注意**：以上文献信息为示例性概括，实际引用时请通过学术数据库(如PubMed、Web of Science)核实标题、作者及具体内容，并优先选择近5年高影响力期刊研究。
The anterior gradient 2 (AGR2) protein, a member of the protein disulfide isomerase (PDI) family, plays critical roles in protein folding, cellular homeostasis, and stress response within the endoplasmic reticulum. It is implicated in regulating cell proliferation, adhesion, and signaling pathways, particularly through interactions with key mediators like EGFR and HER2. AGR2 is also secreted extracellularly, influencing extracellular matrix remodeling and epithelial-mesenchymal transition (EMT), processes linked to cancer progression and metastasis. Overexpression of AGR2 has been observed in numerous cancers, including breast, prostate, lung, and gastrointestinal malignancies, correlating with poor prognosis, drug resistance, and metastatic potential.
AGR2 antibodies are essential tools for detecting AGR2 expression in research and diagnostics. They enable studies on its oncogenic mechanisms, biomarker potential, and therapeutic targeting. Commercially available monoclonal and polyclonal antibodies are used in techniques such as Western blot, immunohistochemistry, and ELISA. However, challenges remain in standardizing detection methods due to AGR2's dual localization (intracellular/extracellular) and post-translational modifications. Recent research explores AGR2-neutralizing antibodies for anticancer therapies and their utility in monitoring treatment response. Despite progress, further validation is needed to address cross-reactivity issues and optimize clinical applicability.
×
